Liposomal irinotecan for advanced neuroendocrine cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have an aggressive neuroendocrine cancer (poorly differentiated, grade 3) that is not in the lung, and it has spread or cannot be removed by surgery
- You have already tried at least one standard chemotherapy, and it stopped working, or your cancer came back within 6 months of finishing treatment
- You have not been treated with irinotecan before
- You are generally able to take care of yourself (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with advanced neuroendocrine carcinoma that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new form of chemotherapy called liposomal irinotecan (Nal-IRI) for people with advanced colorectal cancer or other solid tumors. The goal is to see how well it works and how safe it is in real-world settings.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests whether a liposomal form of the chemotherapy drug irinotecan can help people with advanced neuroendocrine tumors or cancers of the pancreas or gastrointestinal tract. It is designed for those who have not had prior systemic treatment or who have not received it yet.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.